JP6602964B2 - 半フッ素化化合物およびその組成物 - Google Patents
半フッ素化化合物およびその組成物 Download PDFInfo
- Publication number
- JP6602964B2 JP6602964B2 JP2018515472A JP2018515472A JP6602964B2 JP 6602964 B2 JP6602964 B2 JP 6602964B2 JP 2018515472 A JP2018515472 A JP 2018515472A JP 2018515472 A JP2018515472 A JP 2018515472A JP 6602964 B2 JP6602964 B2 JP 6602964B2
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- ophthalmic composition
- composition
- eye
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Description
化合物CF3−(CF2)5−CH(CH3)−(CH2)5−CH3は、次のとおりに調製され得る:ラジカル開始剤の存在下でのヨウ化パーフルオロヘキシルを1−オクテンとラジカル付加させ(ここで、ヨウ化パーフルオロヘキシルを1−オクテンおよびAIBNとしてのラジカル開始剤と混合し、得られた溶液を80度で30分間維持し、そして冷却する)、その後、結果として生じるヨウ素付加物のヒドリド(すなわちLiALH4)によるかまたは水素化(すなわち、Pd/Cなどの触媒の存在下での触媒的水素化)により還元して2−パーフルオロヘキシル−オクタンを形成し、その後、分留により精製する。
CF3−(CF2)5−CH(CH3)−(CH2)5−CH3: 1H−NMR (CDCl3, 400 MHz): 2.17−2.33 (m, 1H, CH), 1.67−1.77 (m, 2H, CH2), 1.25−1.40 (m, 8H, CH2), 1.15 (d, 3H, CH3), 0.9 (t, 3H, CH3)
1.3wt%のCF3−(CF2)5−CH(CH3)−(CH2)5−CH3と95.8wt%のCF3(CF2)5(CH2)7CH3とを含む組成物の細胞毒性を、動物実験との良好な相関および高い感度で細胞毒作用または壊死作用を予測する細胞増殖阻害試験によって評価した。
98.3wt%のCF3(CF2)5(CH2)7CH3と1.2wt%のCF3−(CF2)5−CH(CH3)−(CH2)5−CH3とを含む組成物を、軽度〜中等度の蒸発亢進型ドライアイ疾患を有する患者における観察研究において試験した。1滴あたり約10μlを涙嚢内に分注するように寸法決めされた点眼器の備わった5ml瓶の中に無色透明の液体組成物を供給した。コンタクトレンズを装着している患者は研究から外した。インフォームドコンセントが得られた後、患者は、30〜40μlの1日用量に換算して3〜4滴を毎日両眼に適用するよう勧められた。患者は5〜7週間後に経過観察のために戻った。ベースライン時、および5〜7週目の経過観察のための訪問の時に、29人の患者の臨床データを収集した。
シルマーIおよびTFBUTにおける増加にみることができるとおり、研究期間を経て涙膜流体および涙膜安定性は改善された。遡及的統計解析はこの観察結果を裏付けている、というのも、ベースライン時と経過観察時とでのTFBUTの差が非常に顕著であるからである(対になった両側t検定:p=0.0026(右眼)およびp=0.0006(左眼))。
角膜フルオレセイン染色は、角膜損傷(細胞間接合の喪失)の指標である。ベースライン時に評価1または2と診断された患者の数が経過観察時に評価0へと移っていることから分かるように、データは処置5〜7週間後での角膜損傷の軽減を指し示している。損傷の初期レベル(intial level)に対するこの差は、ウィルコクソンの符号順位検定:p=0.0013(右眼)およびp=0.0041(左眼)で示されているとおり統計学的に顕著である。
患者は、ベースライン時と経過観察のための訪問時との両方において、典型的なドライアイ症候を現在患っているか否かを医者から質問された。下表から分かるように、5〜7週間の処置の後にはDED関連の症候の数がより少なく報告された。
健常な眼ではマイバムはマイボーム腺から透明液体として分泌される。より不透明なより濃いマイバムは、マイボーム腺の機能不全の指標である。ベースライン時と経過観察のための訪問時との両方において、患者のマイバムを記述的に検査した。得られたデータによれば、マイバムの質は数々の事例において改善した。7つの事例において、処置は、表現できるマイバムの低減をもたらした(透明なマイバムから無へと変化した)。
視力または眼圧のどちらにおいても変化は見られず、98.3wt%のCF3(CF2)5(CH2)7CH3と1.2wt%のCF3−(CF2)5−CH(CH3)−(CH2)5−CH3とを含む組成物の5〜7週間にわたる使用が安全であり、これらの眼科パラメータに影響を与えないということが指し示された。
示差走査熱力測定(DSC1、Mettler Toledo、Greifensee、Switzerland)を用いてCF3(CF2)5−CH(CH3)−(CH2)5−CH3とCF3(CF2)5(CH2)7CH3との混合物の構造および相挙動を評価する。DSCは、1℃/分の加熱速度での昇温走査による遷移に関するデータを得るために採用した。密閉された標準的なアルミニウム坩堝(40μl、Mettler Toledo)を使用した。
半フッ素化アルカンCF3(CF2)5(CH2)7CH3とCF3(CF2)5−CH(CH3)−(CH2)5−CH3との混合物の蒸発時間を評価した。各混合物の体積10μLの滴を室温のガラス表面に置いた。蒸発までの時間をビデオ監視により記録した。
M.Frentsら、Altern.to Lab.Anim.、2008(36)p25−32;およびN.Schrageら、Graefes Arch Clin Exp Ophthalmol 2012(250)、1330−1340)に記載のあるものと同様の生体外での眼刺激試験(EVEIT)を用い、ヒアルロン酸(HYLO−COMOD(登録商標)を参照とし、0.01%のBAC(塩化ベンザルコニウム)を陽性対照として、CF3(CF2)5(CH2)7CH3を含む2つの組成物、すなわち半フッ素化アルカンCF3(CF2)5(CH2)7CH3とCF3(CF2)5−CH(CH3)−(CH2)5−CH3との混合物から構成される組成物(組成物AはCF3(CF2)5−CH(CH3)−(CH2)5−CH3を0.17wt%含み、組成物BはCF3(CF2)5−CH(CH3)−(CH2)5−CH3を64wt%含む)について角膜治癒過程に関する比較を行った。
Claims (15)
- CF3(CF2)5(CH2)7CH3とCF3−(CF2)5−CH(CH3)−(CH2)5−CH3とを含む眼科用組成物。
- 少なくとも80wt%のCF3(CF2)5(CH2)7CH3を含む、請求項1に記載の眼科用組成物。
- 25wt%以下のCF3−(CF2)5−CH(CH3)−(CH2)5−CH3を含む、請求項1に記載の眼科用組成物。
- 97wt%のCF3(CF2)5(CH2)7CH3と、3wt%以下のCF3−(CF2)5−CH(CH3)−(CH2)5−CH3とを含む、請求項1〜3のいずれか1項に記載の眼科用組成物。
- 透明な液体溶液として調合されている、請求項1〜4のいずれか1項に記載の眼科用組成物。
- (a)ポリマー、
(b)過フッ素化化合物、および/または
(c)溶解した生理活性成分
を実質的に含まない、請求項1〜5のいずれか1項に記載の眼科用組成物。 - 周囲温度および周囲圧力で10mPa・s以下の絶対粘度を有する、請求項1〜6のいずれか1項に記載の眼科用組成物。
- 医薬として使用するための、請求項1〜7のいずれか1項に記載の眼科用組成物。
- 局所的に涙嚢、下眼瞼内、眼表面または眼組織に投与される、請求項8に記載の眼科用組成物。
- 1日あたり4回以下で前記組成物を投与することを含む、請求項9に記載の眼科用組成物。
- 乾性角結膜炎および/もしくはマイボーム腺機能不全またはそれらに関連した症候もしくは症状の処置に使用するための、請求項8〜10のいずれか1項に記載の眼科用組成物。
- 角膜損傷の処置に使用するための、請求項8〜11のいずれか1項に記載の眼科用組成物。
- 眼表面の潤滑剤として使用するための、請求項8〜11のいずれか1項に記載の眼科用組成物。
- 請求項1〜13のいずれか1項に記載の眼科用組成物と、前記組成物を保持するための容器とを含むキットであって、前記容器が、涙嚢、下眼瞼内、眼表面または眼組織への前記組成物の局所投与に適合した分注手段を備えている、キット。
- 前記分注手段が、8〜15μLの体積を有する滴を分注するなどのための点眼器寸法を備えている、請求項14に記載のキット。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019186433A JP6900442B2 (ja) | 2015-09-30 | 2019-10-09 | 半フッ素化化合物およびその組成物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15187767 | 2015-09-30 | ||
EP15187767.7 | 2015-09-30 | ||
EP15192441.2 | 2015-10-30 | ||
EP15192441 | 2015-10-30 | ||
PCT/EP2016/073263 WO2017055454A1 (en) | 2015-09-30 | 2016-09-29 | Semifluorinated compounds and their compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019186433A Division JP6900442B2 (ja) | 2015-09-30 | 2019-10-09 | 半フッ素化化合物およびその組成物 |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2018531233A JP2018531233A (ja) | 2018-10-25 |
JP2018531233A6 JP2018531233A6 (ja) | 2018-12-13 |
JP2018531233A5 JP2018531233A5 (ja) | 2019-06-06 |
JP6602964B2 true JP6602964B2 (ja) | 2019-11-06 |
Family
ID=57047224
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018515472A Active JP6602964B2 (ja) | 2015-09-30 | 2016-09-29 | 半フッ素化化合物およびその組成物 |
JP2019186433A Active JP6900442B2 (ja) | 2015-09-30 | 2019-10-09 | 半フッ素化化合物およびその組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019186433A Active JP6900442B2 (ja) | 2015-09-30 | 2019-10-09 | 半フッ素化化合物およびその組成物 |
Country Status (11)
Country | Link |
---|---|
US (4) | US20170087100A1 (ja) |
EP (2) | EP3495023B1 (ja) |
JP (2) | JP6602964B2 (ja) |
CN (3) | CN108348777B (ja) |
DE (1) | DE202016008738U1 (ja) |
DK (2) | DK3355990T3 (ja) |
ES (1) | ES2743502T3 (ja) |
HK (2) | HK1257185A1 (ja) |
PL (1) | PL3355990T3 (ja) |
PT (1) | PT3355990T (ja) |
WO (1) | WO2017055454A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020023530A (ja) * | 2015-09-30 | 2020-02-13 | ノバリック ゲーエムベーハー | 半フッ素化化合物およびその組成物 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
CN108283623A (zh) | 2011-05-25 | 2018-07-17 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
ES2625538T3 (es) | 2012-01-23 | 2017-07-19 | Novaliq Gmbh | Composiciones de proteínas estabilizadas basadas en alcanos semifluorados |
MY166228A (en) | 2012-09-12 | 2018-06-22 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
PL3488847T3 (pl) | 2012-09-12 | 2024-04-08 | Novaliq Gmbh | Kompozycje semifluorowanego alkanu |
DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
AU2017281296B2 (en) | 2016-06-23 | 2021-03-11 | Novaliq Gmbh | Topical administration method |
CN109890374A (zh) | 2016-09-22 | 2019-06-14 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
KR20190057338A (ko) | 2016-09-23 | 2019-05-28 | 노바리크 게엠베하 | 시클로스포린을 포함하는 안과 조성물 |
EP3612228B1 (en) | 2017-04-21 | 2023-08-23 | Dermaliq Therapeutics, Inc. | Iodine compositions |
WO2018202835A1 (en) | 2017-05-05 | 2018-11-08 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
EP3618782B1 (en) * | 2017-05-06 | 2021-05-26 | Novaliq GmbH | Drop dispenser |
EP3621601A1 (en) | 2017-05-12 | 2020-03-18 | Novaliq GmbH | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
JP2020535156A (ja) | 2017-09-27 | 2020-12-03 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
CA3076567A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | Ophthalmic compositions |
WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
AU2019342426A1 (en) * | 2018-09-22 | 2021-05-20 | Novaliq Gmbh | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
ES2950878T3 (es) | 2018-09-27 | 2023-10-16 | Dermaliq Therapeutics Inc | Formulación de protección solar de uso tópico |
SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
JP3046346B2 (ja) | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US5152997A (en) | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
GB9114374D0 (en) | 1991-07-03 | 1991-08-21 | Smithkline Beecham Plc | Novel process |
FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
US5370313A (en) | 1994-01-10 | 1994-12-06 | Beard; Walter C. | Sterile liquid dispenser |
DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
IN184589B (ja) | 1996-10-16 | 2000-09-09 | Alza Corp | |
DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
US6645963B2 (en) | 1997-11-05 | 2003-11-11 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
US5851544A (en) | 1997-12-18 | 1998-12-22 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide |
US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
ATE238751T1 (de) | 1998-02-09 | 2003-05-15 | Macrochem Corp | Antimykotischer nagellack |
DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
IL141095A0 (en) | 1998-08-19 | 2002-02-10 | Rtp Pharma Inc | Injectable aqueous dispersions of propofol |
US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
ATE322889T1 (de) | 1999-02-08 | 2006-04-15 | Alza Corp | Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
AU3898700A (en) | 1999-03-15 | 2000-10-04 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
WO2001046134A1 (en) | 1999-12-22 | 2001-06-28 | Alcon Universal Ltd. | 6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE |
US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
DE10042412B4 (de) | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
CA2446060A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
PT1423102E (pt) | 2001-09-04 | 2008-02-25 | Trommsdorff Arzneimittel | Emplastro para o tratamento de disfunções e perturbações o crescimento da unha |
CA2481394A1 (en) | 2002-05-24 | 2003-12-04 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
JP2007503428A (ja) | 2003-08-25 | 2007-02-22 | フォーミックス エルティーディー. | 浸透性医薬発泡剤 |
US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
MXPA06003316A (es) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Formulacion farmaceutica transdermica para minimizar los residuos en la piel. |
JP2007511616A (ja) | 2003-11-19 | 2007-05-10 | バーンズ−ジューイッシュ ホスピタル | 増強された薬物送達 |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
ES2387619T3 (es) | 2004-04-19 | 2012-09-27 | Centre National De La Recherche Scientifique (Cnrs) | Suplementos de tensioactivos pulmonares |
JPWO2005112667A1 (ja) * | 2004-05-20 | 2008-03-27 | 隆史 大森 | 健康食品 |
WO2005123035A1 (en) | 2004-06-08 | 2005-12-29 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
US7063241B2 (en) | 2004-06-10 | 2006-06-20 | Allergan, Inc. | Dispensing tip |
KR20070040381A (ko) | 2004-07-01 | 2007-04-16 | 셰펜스 아이 리써치 | 눈의 장애 및 상태를 치료하는 조성물 및 방법 |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
WO2007008666A2 (en) | 2005-07-08 | 2007-01-18 | Ocularis Pharma, Inc. | Compositions and methods for improving vision using adherent thin films |
WO2007052288A2 (en) | 2005-08-05 | 2007-05-10 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
DE102005050431A1 (de) | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
DE102005055811A1 (de) * | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
AR062046A1 (es) | 2006-07-25 | 2008-08-10 | Osmotica Pharmaceutical Argentina S A | Soluciones oftalmicas |
AU2007281918A1 (en) | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
EP2068828A2 (en) | 2006-09-29 | 2009-06-17 | SurModics, Inc. | Biodegradable ocular implants and methods for treating ocular conditions |
JP5569899B2 (ja) | 2006-11-28 | 2014-08-13 | ウィスコンシン・アラムナイ・リサーチ・ファウンデーション | 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション |
WO2008068775A2 (en) | 2006-12-07 | 2008-06-12 | Sun Pharmaceutical Industries Limited | Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop |
CN200977281Y (zh) | 2006-12-08 | 2007-11-21 | 陈宇 | 带助滴器的滴眼瓶 |
FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
US20090136430A1 (en) | 2007-11-27 | 2009-05-28 | Dugger Harry A | Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
ATE532505T1 (de) | 2008-04-18 | 2011-11-15 | Novaliq Gmbh | Inhalative und instillative verwendung von semifluorierten alkanen als wirkstoffträger im intrapulmonalen bereich |
US20100006600A1 (en) | 2008-07-14 | 2010-01-14 | Dascanio Gustavo A | Fluid dispenser including hydrophobic ring |
US8809261B2 (en) | 2008-10-31 | 2014-08-19 | Elsohly Laboratories, Incorporated | Compositions containing delta-9-THC-amino acid esters and process of preparation |
US20100189765A1 (en) | 2008-11-26 | 2010-07-29 | Erickson Signe R | Implantable ocular drug delivery device and methods |
JP5670200B2 (ja) | 2008-12-02 | 2015-02-18 | ロート製薬株式会社 | 眼科用組成物 |
US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
WO2010150378A1 (ja) | 2009-06-25 | 2010-12-29 | ライオン株式会社 | 眼科用組成物 |
US20110269704A1 (en) | 2009-07-24 | 2011-11-03 | Seigfried Bernd G | Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically |
JP2011024841A (ja) | 2009-07-28 | 2011-02-10 | 健太 ▲浜崎▼ | 点眼補助具 |
EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
DE102010022567A1 (de) * | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2445266B1 (en) * | 2010-10-25 | 2016-03-16 | Alcatel Lucent | Control of access network/access technology selection for the routing of IP traffic by a user equipment, and QoS support, in a multi-access communication system |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
BR112013016661B1 (pt) | 2011-01-04 | 2021-08-03 | Novaliq Gmbh | Emulsões de o/a compreendendo alcanos semifluorados |
CN108283623A (zh) | 2011-05-25 | 2018-07-17 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
JP6023181B2 (ja) | 2011-05-25 | 2016-11-09 | ノバリック ゲーエムベーハー | 爪に投与するための医薬組成物 |
CN202136470U (zh) | 2011-06-08 | 2012-02-08 | 天津市金亿达药用包装材料有限公司 | 便于滴药的眼药瓶 |
US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
ES2625538T3 (es) | 2012-01-23 | 2017-07-19 | Novaliq Gmbh | Composiciones de proteínas estabilizadas basadas en alcanos semifluorados |
US9549966B2 (en) | 2012-02-21 | 2017-01-24 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
US9878000B2 (en) | 2012-06-20 | 2018-01-30 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
PL3488847T3 (pl) * | 2012-09-12 | 2024-04-08 | Novaliq Gmbh | Kompozycje semifluorowanego alkanu |
ES2682064T3 (es) * | 2012-09-12 | 2018-09-18 | Novaliq Gmbh | Composiciones para el lavado de ojos |
MY166228A (en) * | 2012-09-12 | 2018-06-22 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
US10349069B2 (en) * | 2012-12-11 | 2019-07-09 | Sony Interactive Entertainment Inc. | Software hardware hybrid video encoder |
MX2015007931A (es) | 2012-12-18 | 2015-10-05 | Novartis Ag | Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano. |
SG10201710928PA (en) | 2013-03-14 | 2018-02-27 | Panoptica Inc | Ocular formulations for drug-delivery to the posterior segment of the eye |
EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
WO2015053829A1 (en) | 2013-10-09 | 2015-04-16 | Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
CN203524843U (zh) | 2013-10-20 | 2014-04-09 | 吕相瑜 | 自助滴眼液辅助支架 |
CA2931039C (en) | 2013-11-20 | 2022-07-12 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
ES2949040T3 (es) | 2014-03-31 | 2023-09-25 | Amcor Rigid Plastics Usa Llc | Recipiente de liberación controlada |
EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
WO2016025560A1 (en) | 2014-08-13 | 2016-02-18 | University Of Florida Research Foundation, Inc. | Preservative removal from eye drops |
MA41299A (fr) | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
PT3355990T (pt) | 2015-09-30 | 2019-09-11 | Novaliq Gmbh | Compostos semifluorados e as suas composições |
AU2017281296B2 (en) | 2016-06-23 | 2021-03-11 | Novaliq Gmbh | Topical administration method |
CN109890374A (zh) | 2016-09-22 | 2019-06-14 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
KR20190057338A (ko) | 2016-09-23 | 2019-05-28 | 노바리크 게엠베하 | 시클로스포린을 포함하는 안과 조성물 |
CA3036313A1 (en) | 2016-09-28 | 2018-04-05 | Novaliq Gmbh | Compositions comprising a cannabinoid receptor binding ligand |
CA3045733C (en) | 2016-12-22 | 2024-01-16 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
CN110267645A (zh) | 2016-12-23 | 2019-09-20 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
EP3621601A1 (en) | 2017-05-12 | 2020-03-18 | Novaliq GmbH | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
-
2016
- 2016-09-29 PT PT16775225T patent/PT3355990T/pt unknown
- 2016-09-29 ES ES16775225T patent/ES2743502T3/es active Active
- 2016-09-29 JP JP2018515472A patent/JP6602964B2/ja active Active
- 2016-09-29 WO PCT/EP2016/073263 patent/WO2017055454A1/en active Application Filing
- 2016-09-29 PL PL16775225T patent/PL3355990T3/pl unknown
- 2016-09-29 DE DE202016008738.0U patent/DE202016008738U1/de active Active
- 2016-09-29 EP EP18210942.1A patent/EP3495023B1/en active Active
- 2016-09-29 DK DK16775225.2T patent/DK3355990T3/da active
- 2016-09-29 CN CN201680056188.9A patent/CN108348777B/zh active Active
- 2016-09-29 CN CN202010471109.9A patent/CN111743882A/zh active Pending
- 2016-09-29 CN CN201910679312.2A patent/CN110403923B/zh active Active
- 2016-09-29 DK DK18210942.1T patent/DK3495023T3/da active
- 2016-09-29 EP EP16775225.2A patent/EP3355990B1/en active Active
- 2016-09-29 US US15/280,306 patent/US20170087100A1/en not_active Abandoned
-
2018
- 2018-11-05 US US16/180,994 patent/US10682315B2/en active Active
- 2018-12-17 HK HK18116122.7A patent/HK1257185A1/zh unknown
- 2018-12-17 HK HK18116120.9A patent/HK1257183B/zh unknown
-
2019
- 2019-10-09 JP JP2019186433A patent/JP6900442B2/ja active Active
-
2020
- 2020-05-14 US US16/874,617 patent/US11357738B2/en active Active
-
2022
- 2022-06-06 US US17/833,836 patent/US20220370377A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020023530A (ja) * | 2015-09-30 | 2020-02-13 | ノバリック ゲーエムベーハー | 半フッ素化化合物およびその組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN108348777A (zh) | 2018-07-31 |
US20190070125A1 (en) | 2019-03-07 |
EP3495023A1 (en) | 2019-06-12 |
CN110403923B (zh) | 2021-09-21 |
US20170087100A1 (en) | 2017-03-30 |
CN108348777B (zh) | 2020-04-28 |
WO2017055454A1 (en) | 2017-04-06 |
US20200338015A1 (en) | 2020-10-29 |
DE202016008738U1 (de) | 2019-04-09 |
HK1257185A1 (zh) | 2019-10-18 |
US20220370377A1 (en) | 2022-11-24 |
JP2018531233A (ja) | 2018-10-25 |
JP6900442B2 (ja) | 2021-07-07 |
EP3355990B1 (en) | 2019-06-12 |
JP2020023530A (ja) | 2020-02-13 |
US10682315B2 (en) | 2020-06-16 |
HK1257183B (zh) | 2020-06-12 |
EP3355990A1 (en) | 2018-08-08 |
PL3355990T3 (pl) | 2019-11-29 |
US11357738B2 (en) | 2022-06-14 |
DK3495023T3 (da) | 2020-07-20 |
ES2743502T3 (es) | 2020-02-19 |
CN111743882A (zh) | 2020-10-09 |
EP3495023B1 (en) | 2020-04-22 |
CN110403923A (zh) | 2019-11-05 |
PT3355990T (pt) | 2019-09-11 |
DK3355990T3 (da) | 2019-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6602964B2 (ja) | 半フッ素化化合物およびその組成物 | |
JP7050741B2 (ja) | 眼投与用の半フッ素化化合物 | |
JP2018531233A6 (ja) | 半フッ素化化合物およびその組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190425 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190425 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20190425 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190515 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190820 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191009 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6602964 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |